Form 4: Nurix CFO Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report 30 October 2025 6:06 PM

📋All filings for Nurix Therapeutics, INC

Nurix Therapeutics CFO Hans van Houte reported the exercise of restricted stock units and subsequent sale of shares to cover tax withholding obligations.

Summary

Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on October 30, 2025.
Mr. van Houte acquired a total of 11,494 shares of Common Stock through the exercise/conversion of Restricted Stock Units (RSUs) at a price of $0 per share.
The acquisitions consisted of 2,886 shares, 2,000 shares, 3,750 shares, and 2,858 shares from different RSU grants.
Concurrently, Mr. van Houte disposed of 3,130 shares of Common Stock at a weighted average sale price of $12.7967 per share.
These sales were non-discretionary, mandated by the Issuer's equity incentive plans to cover tax withholding obligations associated with the vesting of RSUs.
Following these transactions, Mr. van Houte directly beneficially owns 43,876 shares of Common Stock.
The RSUs represent a contingent right to receive one share of common stock each and do not expire, but rather vest or are canceled.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of restricted stock units and a subsequent 'sell to cover' sale to satisfy tax obligations. This is a non-discretionary event and does not reflect a change in management's sentiment towards the company's prospects.

Positives

The vesting of 11,494 Restricted Stock Units represents earned equity compensation for the Chief Financial Officer.
The company's equity incentive plans are functioning as intended to compensate executives.

Negatives

The direct beneficial ownership of Common Stock by the CFO decreased by 3,130 shares due to the 'sell to cover' transaction.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly 'sell to cover' sales for tax obligations upon RSU vesting, are common and routine events in publicly traded companies, especially in the biotechnology sector where equity compensation is a significant component of executive pay.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Equity Incentive Plan Operation	The company's equity incentive plans mandate a 'sell to cover' transaction to satisfy tax withholding obligations upon RSU vesting.	N/A	Ensures compliance with tax regulations for equity compensation and provides a standardized method for employees to meet tax liabilities without requiring personal funds upfront.

Stakeholder Impact

Shareholders: A minor dilution effect from the issuance of shares upon RSU vesting, partially offset by the sale of shares in the open market. The transaction volume is small relative to the company's total outstanding shares.
Employees (specifically Hans van Houte): Realization of earned equity compensation, with a portion used to cover tax liabilities.

Next Steps

Future vesting of remaining Restricted Stock Units for Hans van Houte on their respective schedules, subject to continued provision of services to the Issuer.

Key Dates

Date	Description
04/30/2022	First quarterly increment vesting date for a grant of RSUs (2,886 shares).
07/30/2023	First quarterly increment vesting date for a grant of RSUs (2,000 shares).
07/30/2024	First quarterly increment vesting date for a grant of RSUs (3,750 shares).
07/30/2025	First quarterly increment vesting date for a grant of RSUs (2,858 shares).
10/30/2025	Transaction date for RSU exercises and subsequent share sales.

Recommendation

hold

This Form 4 filing details a routine 'sell to cover' transaction by a company officer to satisfy tax obligations upon the vesting of restricted stock units. It is explicitly stated as non-discretionary and does not indicate a change in the officer's or company's outlook. As such, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation for Nurix Therapeutics.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, CFO, Hans van Houte, Equity Compensation, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.